glp 1 receptor agonist moa Frontiers Oral Small-Molecule GLP-1 Receptor Agonists:

Biological plausibility suggests BDNF receptor desensitization could occur with chronic stimulation a 2025 rodent study found that BDNF-stimulating compounds led to receptor downregulation within 16 weeks, requiring higher doses to maintain effect

Puede acelerar la recuperacin muscular

Compounded GLP-1 medications are not FDA-approved finished products and outcomes are not guaranteed

Further research is warranted to clarify perioperative management guidelines in this setting

In conclusion, this review synthesizes molecular insights and clinical evidence to underscore GLP-1RAs potential as multi-targeted disease-modifying agents, urging further research to translate preclinical promise into safe, effective ocular therapies